KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $77.0 million.

  • Ionis Pharmaceuticals' Current Deferred Revenue rose 127.34% to $77.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.0 million, marking a year-over-year increase of 127.34%. This contributed to the annual value of $79.0 million for FY2024, which is 4773.37% down from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $77.0 million for Q3 2025, which was up 127.34% from $75.9 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Current Deferred Revenue peaked at $204.8 million during Q3 2023, and registered a low of $75.9 million during Q2 2025.
  • Its 5-year average for Current Deferred Revenue is $102.0 million, with a median of $94.1 million in 2024.
  • In the last 5 years, Ionis Pharmaceuticals' Current Deferred Revenue surged by 10583.05% in 2023 and then tumbled by 6288.62% in 2024.
  • Ionis Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $97.7 million in 2021, then dropped by 7.3% to $90.6 million in 2022, then soared by 66.85% to $151.1 million in 2023, then tumbled by 47.73% to $79.0 million in 2024, then decreased by 2.54% to $77.0 million in 2025.
  • Its Current Deferred Revenue stands at $77.0 million for Q3 2025, versus $75.9 million for Q2 2025 and $81.1 million for Q1 2025.